A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management
Latest Information Update: 11 Jul 2025
At a glance
- Drugs Enobosarm (Primary) ; Semaglutide (Primary)
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- Acronyms QUALITY
- Sponsors Veru Healthcare
Most Recent Events
- 24 Jun 2025 According to Veru Healthcare Media Release, the company looks forward to report the full Phase 2b QUALITY and Maintenance Extension clinical trial efficacy and safety data at future leading scientific conferences and in publications.
- 24 Jun 2025 Positive topline results presented in the Veru Healthcare Media Release.
- 28 May 2025 Topline results presented in a Verus Pharmaceuticals media release